Ludmir Ethan B, Arya Ritu, Wu Yuan, Palta Manisha, Willett Christopher G, Czito Brian G
Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.
Department of Biostatistics and Bioinformatics, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
Ann Surg Oncol. 2016 Mar;23(3):856-62. doi: 10.1245/s10434-015-4907-3. Epub 2015 Oct 19.
The role of adjuvant radiation therapy (RT) in the treatment of resected, locally advanced colon cancer is unclear. One randomized controlled trial (Intergroup-0130) addressed this question but failed to meet its accrual goals. Since this trial, few attempts have been made to reassess the role of RT in this clinical setting.
Sixty-two patients with non-metastatic, American Joint Committee on Cancer 7th edition stage T4 colonic adenocarcinoma were treated at our institution between 2000 and 2013. All underwent curative-intent surgery. Sixteen patients underwent resection only, 33 patients received adjuvant chemotherapy (ChT), and 13 patients received adjuvant chemoradiation therapy (CRT).
Patients receiving adjuvant CRT were more likely to have T4b (vs. T4a) disease and were more likely to undergo R1 or R2 resection compared with those receiving adjuvant ChT alone. Despite this, multivariate analysis demonstrated that treatment with adjuvant CRT (vs. adjuvant ChT) enhanced locoregional control and disease-free survival (hazard ratio 0.044 and 0.145, respectively; p < 0.05).
Adjuvant RT for T4 colon cancers may be appropriate in select patients, specifically those with T4b lesions and/or residual disease following resection.
辅助放疗(RT)在已切除的局部晚期结肠癌治疗中的作用尚不清楚。一项随机对照试验(Intergroup - 0130)探讨了这个问题,但未达到其入组目标。自该试验以来,很少有人尝试重新评估RT在这种临床情况下的作用。
2000年至2013年期间,我们机构治疗了62例非转移性、美国癌症联合委员会第7版T4期结肠腺癌患者。所有患者均接受了根治性手术。16例患者仅接受了手术切除,33例患者接受了辅助化疗(ChT),13例患者接受了辅助放化疗(CRT)。
与仅接受辅助ChT的患者相比,接受辅助CRT的患者更有可能患有T4b(相对于T4a)疾病,并且更有可能接受R1或R2切除。尽管如此,多变量分析表明,辅助CRT治疗(相对于辅助ChT)可增强局部区域控制和无病生存期(风险比分别为0.044和0.145;p < 0.05)。
对于T4期结肠癌,辅助放疗可能适用于特定患者,特别是那些患有T4b病变和/或切除后有残留疾病的患者。